Skip to main content

Cytotoxic T-lymphocyte-associated antigen-4.

Publication ,  Journal Article
Salama, AKS; Hodi, FS
Published in: Clin Cancer Res
July 15, 2011

Cancer immunotherapy relies on the ability of the immune system to target tumor-specific antigens to generate an immune response. This initial response requires both binding of the MHC/antigen peptide to T-cell receptor complex, along with a second costimulatory signal created by the binding of CD28 on the T cell, with B7 located on the antigen-presenting cell. Regulatory checkpoints, such as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), serve to attenuate this signal, thereby preventing autoimmunity. Its key role in regulating the immune system has made CTLA-4 an attractive therapeutic target for cancer, with the development of fully human monoclonal antibodies that have successfully targeted CTLA-4 in clinical trials. Augmentation of the immune response via blockade of CTLA-4 represents a significant advance in the field of oncology and has shown an improvement in survival for patients with metastatic melanoma. An increased understanding of the components of this pathway and the identification of other methods to modulate the immune system hold great promise for future therapy.

Duke Scholars

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

July 15, 2011

Volume

17

Issue

14

Start / End Page

4622 / 4628

Location

United States

Related Subject Headings

  • Translational Research, Biomedical
  • T-Lymphocytes
  • Oncology & Carcinogenesis
  • Neoplasms
  • Molecular Targeted Therapy
  • Lymphocyte Activation
  • Humans
  • CTLA-4 Antigen
  • Antineoplastic Agents
  • Antibodies, Monoclonal
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Salama, A. K. S., & Hodi, F. S. (2011). Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res, 17(14), 4622–4628. https://doi.org/10.1158/1078-0432.CCR-10-2232
Salama, April K. S., and F Stephen Hodi. “Cytotoxic T-lymphocyte-associated antigen-4.Clin Cancer Res 17, no. 14 (July 15, 2011): 4622–28. https://doi.org/10.1158/1078-0432.CCR-10-2232.
Salama AKS, Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res. 2011 Jul 15;17(14):4622–8.
Salama, April K. S., and F. Stephen Hodi. “Cytotoxic T-lymphocyte-associated antigen-4.Clin Cancer Res, vol. 17, no. 14, July 2011, pp. 4622–28. Pubmed, doi:10.1158/1078-0432.CCR-10-2232.
Salama AKS, Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res. 2011 Jul 15;17(14):4622–4628.

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

July 15, 2011

Volume

17

Issue

14

Start / End Page

4622 / 4628

Location

United States

Related Subject Headings

  • Translational Research, Biomedical
  • T-Lymphocytes
  • Oncology & Carcinogenesis
  • Neoplasms
  • Molecular Targeted Therapy
  • Lymphocyte Activation
  • Humans
  • CTLA-4 Antigen
  • Antineoplastic Agents
  • Antibodies, Monoclonal